Business Wire

THALES

27.10.2021 09:02:11 CEST | Business Wire | Press release

Share
Majority of Businesses Don’t Protect Their Sensitive Data in the Cloud, Finds Thales

The 2021 Thales Global Cloud Security Study , commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence, reports that 40% of organisations have experienced a cloud-based data breach in the past 12 months. Despite increasing cyber-attacks targeting data in the cloud, the vast majority (83%) of businesses are still failing to encrypt half of the sensitive data they store in the cloud, raising even greater concerns as to the impact cyber criminals can have.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005044/en/

Pandemic has accelerated cloud transformation

Cloud adoption is on the rise and businesses are continuing to diversify the way they use cloud solutions. Globally, 57% of respondents reported they make use of two or more cloud infrastructure providers, whilst almost a quarter (24%) of organisations flagged that the majority of their workloads and data now reside in the cloud. In fact, according to a recent study by McKinsey & Company, companies globally have accelerated their cloud adoption by three years compared to pre-pandemic adoption rates. This marks a significant shift in the use of cloud-based solutions, from being purely data storage solutions, to environments in which data is used transactionally and supports day-to-day business operations.

Security in the cloud is mixed

According to the study, one fifth (21%) of businesses host the majority of their sensitive data in the cloud, while 40% reported a breach in the last year. There are some common trends as to where companies turn when considering how to secure their cloud infrastructure, with 33% reporting multi-factor authentication (MFA) as being a central part of their cybersecurity strategy. However, only 17% of those surveyed have encrypted more than half of the data they store in the cloud. This figure drops to 15% where organisations have adopted a multicloud approach.

Even where businesses protect their data with encryption, 34% of organisations leave the control of keys to service providers rather than retaining control themselves. Where large numbers of organisations fail to protect their data sufficiently with encryption, limiting potential access points becomes even more critical. However, nearly half (48%) of business leaders globally admitted their organisation does not have a Zero Trust strategy, and a quarter (25%) aren’t even considering one.

Complexity as a concern

Businesses share common concerns about the increasing complexity of cloud services. Almost half (46%) of global respondents claimed managing privacy and data protection in the cloud is more complex than on-premises solutions.

Hybrid models are common with many organisations not moving entirely to the cloud. 55% of businesses have indicated a preference for a ‘lift & shift’ approach to cloud adoption over re-architecting, as cloud becomes a more integrated part of the business infrastructure.

Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales comments: “Organisations across the world are struggling to navigate the increased complexity that comes with greater adoption of cloud-based solutions. A robust security strategy is essential to ensuring data and business operations remain secure. With nearly every business reliant on the cloud to some extent, it is vital that security teams have the ability to discover, protect, and maintain control of their data.”

Fernando Montenegro Principal Research Analyst, Information Security at 451 Research, part of S&P Global Market Intelligence added from the 2021 Thales Global Cloud Security Study: “Protecting customer data is always the priority, and organisations should strongly consider reviewing their strategies and approaches to proactively protect data in cloud. This includes understanding the role of specific technologies including encryption and key management, as well as the shared responsibilities between providers and their customers. As data privacy and sovereignty regulations grow, it will be paramount that organisations have a clear understanding of how they remain responsible for data security and make clear decisions about who is in control and who can access their sensitive data.”

Thales and 451 Research will discuss the global findings in more detail during its upcoming Cloud Security Summit on 17 November 2021. To join, please visit the registration page .

About the 2021 Thales Global Cloud Security Study

The 2021 Thales Cloud Security Study was commissioned by Thales and conducted by 451 Research, part of S&P Global Market Intelligence and includes the viewpoints from more than 2,600 executives with responsibility for or influence over IT and data security. Respondents were from 16 countries/regions: Australia, Brazil, France, Germany, Hong Kong, India, Japan, Mexico, Netherlands, New Zealand, Singapore, South Korea, Sweden, the United Arab Emirates, the United Kingdom, and the United States. Organisations represented a range of industries, with a primary emphasis on healthcare, financial services, retail, technology, and federal government. Job titles ranged from C-level executives including CEO, CFO, Chief Data Officer, CISO, Chief Data Scientist, and Chief Risk Officer, to SVP/VP, IT Administrator, Security Analyst, Security Engineer, and Systems Administrator. Respondents represented a broad range of organizational sizes, with the majority ranging from 500 to 10,000 employees. The survey was conducted in January - February 2021.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye